Cannabis and Gut Health: How CBG, CBD, and THC Support Your Digestive Tract

The Endocannabinoid System in Your Gut

The ECS wasn’t discovered until the 1990s, which is part of why it doesn’t have the same textbook presence as the nervous or immune systems. That’s starting to change. A 2023 review by researchers at the Mayo Clinic, published in Clinical Gastroenterology and Hepatology (PMC10872845), confirmed that CB1 and CB2 receptors and their signaling pathways are present throughout the digestive system with well-documented roles in gut motility, immune response, visceral pain signaling, and intestinal barrier integrity.

CB1 receptors are densest in the enteric nervous system, sometimes called the “second brain,” which runs along the entire GI tract and handles most of the gut’s autonomous function. CB2 receptors are concentrated in the immune cells that line the gut wall. Phytocannabinoids interact with both. Different cannabinoids hit these receptors at different affinities and through different mechanisms, which is why CBG, CBD, and THC can all affect the gut while doing different things.

CBG: The Strongest Gut-Specific Evidence

CBG (cannabigerol) is the precursor from which most other cannabinoids are produced in the hemp plant, which is why researchers sometimes call it the “mother cannabinoid.” It’s present in smaller concentrations than CBD in most hemp flower, so it gets less attention.

The colitis model

A foundational study in Biochemical Pharmacology (PMID 23415610) found that CBG significantly reduced inflammation, oxidative stress, and intestinal damage in a mouse model of colitis. It reduced key inflammatory markers including iNOS expression and interleukin-1beta. The researchers concluded CBG should be considered for clinical experimentation in IBD patients. A 2024 follow-up in the Journal of Pharmacology and Experimental Therapeutics (JPET 2024) extended this finding: a high-CBG hemp extract dramatically reduced disease severity in a colitis model and modulated the colonic microbiome. The extract demonstrated clade-specific antibacterial activity against human gut isolates in vitro, targeting harmful bacteria while leaving beneficial populations intact.

The IBS clinical trial

In a 2023 proof-of-concept trial published in the American College of Gastroenterology journal (ACG 2023), patients with IBS who took a CBD/CBG oral tincture twice daily reported a 33% reduction in abdominal pain scores over two weeks. Three women followed for 24 weeks also reported no menstrual cramping, a notable finding given the documented overlap between IBS and dysmenorrhea. No adverse events were reported. This is a small trial and larger controlled studies are needed, but it’s human data on a CBD/CBG combination in an IBS population, which is rare.

How CBG works on gut tissue

CBG appears to engage the gut through multiple receptor pathways simultaneously: CB2 receptors in immune cells (reducing inflammatory cytokine release), TRPV1 channels in the gut lining (modulating pain signaling), and 5-HT1A receptors (addressing nausea and motility). Non-psychoactive at standard doses. “I’ve been using it for about three weeks now and it seems to be making a big difference,” Amey S. (CBG Tincture).

CBD and the Gut-Brain Axis

Most people reach for CBD for anxiety or sleep. The gut-brain axis is a two-way street, and CBD works both ends of it. Stress and gut disorders travel together so consistently that the mechanism isn’t coincidental: the vagus nerve directly connects the brain to the enteric nervous system, and the amygdala’s threat-response loop directly affects gut motility and secretion.

CBD’s gut-specific mechanisms go beyond the stress-gut connection. A 2024 review in the International Journal of Molecular Sciences (IJMS 2024) found that both THC and CBD may help restore normal intestinal permeability after disruption by influencing the synthesis of tight junction proteins, the molecular structures that hold the intestinal cell wall together. Disruption of these proteins is the mechanism underlying what’s commonly called “leaky gut.” CBD appears to act through CB1 and TRPV1 receptors in the gut lining, both of which are involved in how pain signals transmit and how the epithelial barrier is maintained.

A 2022 review in the American Journal of Gastroenterology found that CBD may support people with functional gut disorders, particularly around visceral pain. Visceral pain is the deep, hard-to-describe gut discomfort that doesn’t always show up on a scan but absolutely derails a day. It’s the most undertreated symptom category in GI medicine, and CBD’s TRPV1 activity gives it a mechanistically plausible role there.

THC and CBN: Supporting Roles

THC and motility

THC has the most extensive GI research of any cannabinoid, partly because it’s been studied longer and partly because its effects are unmistakable. The Mayo Clinic review noted that THC generally slows GI motility through CB1 receptor activation in the enteric nervous system. For conditions involving overactive motility (diarrhea-predominant IBS, urgency, cramping), slower transit is the therapeutic goal. THC also has well-established anti-nausea properties through CB1 receptors in the stomach, and it has been used medically in chemotherapy patients for decades on that basis. CB1 activation reduces gastric acid secretion and has protective effects on the gastric lining.

The psychoactive effect limits THC’s daytime utility for most users. Delta 9 THC gummies in a low-dose formula (the approach in TribeTokes’ Everyday Balance line) are a more controlled entry point than higher-potency formats. Delta 9 THC products will produce a positive result on standard drug tests.

CBN and the NREM-gut repair cycle

CBN (cannabinol) is most recognized as a sleep cannabinoid, and the gut-sleep connection is more specific than most people realize. The relevant mechanism isn’t sleep in general. It’s NREM sleep in particular. During the deep slow-wave stages of NREM sleep, the gut does the bulk of its repair work: tight junction proteins are resynthesized, intestinal epithelial cells undergo their renewal cycle, and the enteric nervous system resets from the day’s inflammatory and motility load. Growth hormone, released in pulses during slow-wave NREM, supports intestinal epithelial cell regeneration directly. Shortened or fragmented NREM specifically is associated with increased intestinal permeability, elevated gut inflammatory markers, and altered gut microbiome composition (independent of total sleep time). Getting eight hours of light sleep produces different gut outcomes than six hours of high-quality NREM-rich sleep.

Gut dysbiosis compounds the problem in the other direction. A dysregulated microbiome elevates lipopolysaccharide levels in circulation, which crosses the blood-brain barrier and disrupts sleep architecture, specifically suppressing slow-wave NREM. It is a genuine bidirectional loop: poor NREM degrades gut barrier integrity, and poor gut integrity degrades NREM quality. CBN’s CB1 and CB2 receptor activity, alongside its sedating properties, may support the depth and duration of NREM sleep rather than just total sleep time.

Why Full-Spectrum Coverage Matters

Cannabinoids don’t work in isolation in the gut any more than they do in other systems. A 2023 paper in Medical Cannabis and Cannabinoids (Karger 2023) documented that the ECS is deeply interwoven with both the gut microbiome and the gut-brain axis, and that multiple receptor types are involved: CB1, CB2, TRPV1, GPR55, and PPARalpha. No single cannabinoid engages all of them. A full-spectrum product with preserved minor cannabinoids and terpenes covers more of this receptor landscape than an isolate does.

Beta-caryophyllene, a terpene present in full-spectrum hemp, is also a CB2 agonist. It adds another anti-inflammatory layer at the gut’s immune cell receptors independent of the cannabinoid content. Full-spectrum formulations get you this kind of coverage by default; isolates don’t.

Cannabinoid Gut-Health Comparison

TribeTokes Products for Gut Health